Article (Published version) (521 Kb) - Limited access to UNIGE
Pacritinib: a new agent for the management of myelofibrosis?
|Published in||Expert Opinion on Pharmacotherapy. 2015, vol. 16, no. 15, p. 2381-90|
|Abstract||Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F, MPL, CALR) and constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway. MF is often characterised by debilitating symptoms and JAK inhibitors (JAKIs) have revolutionised available therapeutic options. Ruxolitinib, a JAK1 and 2 inhibitor, is the only currently approved agent. Several other JAKIs are undergoing evaluation in the clinical trial setting and Pacritinib , a novel JAK2 and FLT3 inhibitor, is at an advanced stage of investigation with recent completion of a Phase III trial and another ongoing.|
|BEAUVERD, Yan, MCLORNAN, Donal P, HARRISON, Claire N. Pacritinib: a new agent for the management of myelofibrosis?. In: Expert Opinion on Pharmacotherapy, 2015, vol. 16, n° 15, p. 2381-90. https://archive-ouverte.unige.ch/unige:84049|